Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients.
BACKGROUND
Intravesical instillations with bacillus Calmette-Guérin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder.


METHODS
There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS.


RESULTS
Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection.


CONCLUSIONS
Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.
Palou
Juan
J
Urology Department, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain. jpalou@fundacio-puigvert.es
Angerri
Oriol
O
Segarra
José
J
Caparrós
Juan
J
Guirado
Luis
L
Diaz
Juan Manuel
JM
Salvador-Bayarri
José
J
Villavicencio-Mavrich
Humberto
H
D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000601:surgery; D018572:Disease-Free Survival; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery
D001500:BCG Vaccine